Bert Vogelstein, M.D.
Advisory Board Member
Bert Vogelstein was the first scientist to determine the molecular basis of a common human cancer. He and his colleagues demonstrated that colorectal tumors result from the gradual accumulation of genetic alterations in specific oncogenes and tumor suppressor genes. His work on colorectal cancers forms the paradigm for much of modern cancer research, with major implications for improved diagnostic and therapeutic strategies. Bert and his colleagues were also the first to determine the sequences of all genes in any cancer. They thereby were able to determine the genetic landscapes of more than a dozen tumor types. Together with earlier studies, their work has provided the conceptual basis for “precision medicine.”
To facilitate this work, Bert and his colleagues have invented several disruptive technologies and have been awarded more than 150 U.S. patents. Among these are digital PCR as well as essential components of three commercially successful next generation sequencing instruments. These inventions have been widely licensed by industry and provided the basis of four diagnostic companies for which he served as founder or senior advisor (EXACT Sciences, Inostics, Personal Genome Diagnostics (PGDx), and PapGene).
Bert earned a B.A. degree from University of Pennsylvania in Mathematics, a M.D. degree from The Johns Hopkins School of Medicine and completed his residency at Johns Hopkins Hospital.